nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP3A4—Topotecan—ovarian cancer	0.0414	0.272	CbGbCtD
Sitaxentan—CYP2C9—Paclitaxel—ovarian cancer	0.0353	0.232	CbGbCtD
Sitaxentan—CYP3A4—Vinorelbine—ovarian cancer	0.0292	0.192	CbGbCtD
Sitaxentan—CYP3A4—Paclitaxel—ovarian cancer	0.0205	0.135	CbGbCtD
Sitaxentan—CYP3A4—Docetaxel—ovarian cancer	0.0148	0.0973	CbGbCtD
Sitaxentan—EDNRB—myometrium—ovarian cancer	0.0128	0.0913	CbGeAlD
Sitaxentan—CYP3A4—Doxorubicin—ovarian cancer	0.0111	0.0726	CbGbCtD
Sitaxentan—EDNRA—myometrium—ovarian cancer	0.0106	0.0755	CbGeAlD
Sitaxentan—EDNRB—uterine cervix—ovarian cancer	0.00996	0.071	CbGeAlD
Sitaxentan—EDNRB—decidua—ovarian cancer	0.00949	0.0677	CbGeAlD
Sitaxentan—EDNRB—endometrium—ovarian cancer	0.009	0.0642	CbGeAlD
Sitaxentan—EDNRB—uterus—ovarian cancer	0.0083	0.0592	CbGeAlD
Sitaxentan—EDNRA—uterine cervix—ovarian cancer	0.00823	0.0587	CbGeAlD
Sitaxentan—EDNRA—decidua—ovarian cancer	0.00784	0.0559	CbGeAlD
Sitaxentan—EDNRA—endometrium—ovarian cancer	0.00744	0.0531	CbGeAlD
Sitaxentan—EDNRA—uterus—ovarian cancer	0.00686	0.0489	CbGeAlD
Sitaxentan—EDNRB—female gonad—ovarian cancer	0.00679	0.0484	CbGeAlD
Sitaxentan—EDNRB—vagina—ovarian cancer	0.00675	0.0481	CbGeAlD
Sitaxentan—EDNRB—testis—ovarian cancer	0.00602	0.043	CbGeAlD
Sitaxentan—EDNRA—female gonad—ovarian cancer	0.00561	0.04	CbGeAlD
Sitaxentan—EDNRA—vagina—ovarian cancer	0.00558	0.0398	CbGeAlD
Sitaxentan—EDNRA—testis—ovarian cancer	0.00498	0.0355	CbGeAlD
Sitaxentan—EDNRB—lymph node—ovarian cancer	0.00436	0.0311	CbGeAlD
Sitaxentan—EDNRA—lymph node—ovarian cancer	0.00361	0.0257	CbGeAlD
Sitaxentan—CYP2C19—vagina—ovarian cancer	0.00238	0.017	CbGeAlD
Sitaxentan—CYP2C9—female reproductive system—ovarian cancer	0.00204	0.0146	CbGeAlD
Sitaxentan—CYP3A4—female reproductive system—ovarian cancer	0.00156	0.0111	CbGeAlD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000316	0.000491	CcSEcCtD
Sitaxentan—Nausea—Topotecan—ovarian cancer	0.000314	0.000489	CcSEcCtD
Sitaxentan—Discomfort—Paclitaxel—ovarian cancer	0.000314	0.000488	CcSEcCtD
Sitaxentan—Muscular weakness—Epirubicin—ovarian cancer	0.000312	0.000486	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000312	0.000486	CcSEcCtD
Sitaxentan—Dry mouth—Paclitaxel—ovarian cancer	0.000311	0.000483	CcSEcCtD
Sitaxentan—Diarrhoea—Vinorelbine—ovarian cancer	0.00031	0.000482	CcSEcCtD
Sitaxentan—Ataxia—Doxorubicin—ovarian cancer	0.000308	0.000479	CcSEcCtD
Sitaxentan—Nausea—Melphalan—ovarian cancer	0.000308	0.000479	CcSEcCtD
Sitaxentan—Confusional state—Paclitaxel—ovarian cancer	0.000307	0.000478	CcSEcCtD
Sitaxentan—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000307	0.000478	CcSEcCtD
Sitaxentan—Asthma—Epirubicin—ovarian cancer	0.000306	0.000476	CcSEcCtD
Sitaxentan—Dehydration—Doxorubicin—ovarian cancer	0.000305	0.000474	CcSEcCtD
Sitaxentan—Oedema—Paclitaxel—ovarian cancer	0.000305	0.000474	CcSEcCtD
Sitaxentan—Muscle spasms—Docetaxel—ovarian cancer	0.000304	0.000473	CcSEcCtD
Sitaxentan—Eosinophilia—Epirubicin—ovarian cancer	0.000303	0.000472	CcSEcCtD
Sitaxentan—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000303	0.000471	CcSEcCtD
Sitaxentan—Infection—Paclitaxel—ovarian cancer	0.000303	0.000471	CcSEcCtD
Sitaxentan—CYP2C19—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000302	0.00468	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—BCL9—ovarian cancer	0.000301	0.00467	CbGpPWpGaD
Sitaxentan—Dry skin—Doxorubicin—ovarian cancer	0.0003	0.000467	CcSEcCtD
Sitaxentan—Dizziness—Vinorelbine—ovarian cancer	0.000299	0.000466	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.000299	0.000466	CcSEcCtD
Sitaxentan—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000299	0.000466	CcSEcCtD
Sitaxentan—Nervous system disorder—Paclitaxel—ovarian cancer	0.000299	0.000465	CcSEcCtD
Sitaxentan—Angina pectoris—Epirubicin—ovarian cancer	0.000298	0.000464	CcSEcCtD
Sitaxentan—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000298	0.000464	CcSEcCtD
Sitaxentan—Tachycardia—Paclitaxel—ovarian cancer	0.000297	0.000462	CcSEcCtD
Sitaxentan—Breast disorder—Doxorubicin—ovarian cancer	0.000296	0.000461	CcSEcCtD
Sitaxentan—Skin disorder—Paclitaxel—ovarian cancer	0.000296	0.00046	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000295	0.000459	CcSEcCtD
Sitaxentan—Bronchitis—Epirubicin—ovarian cancer	0.000294	0.000458	CcSEcCtD
Sitaxentan—Anaemia—Docetaxel—ovarian cancer	0.000292	0.000455	CcSEcCtD
Sitaxentan—Pancytopenia—Epirubicin—ovarian cancer	0.000291	0.000452	CcSEcCtD
Sitaxentan—Anorexia—Paclitaxel—ovarian cancer	0.00029	0.000452	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000289	0.00045	CcSEcCtD
Sitaxentan—Muscular weakness—Doxorubicin—ovarian cancer	0.000289	0.00045	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—ovarian cancer	0.000288	0.00447	CbGpPWpGaD
Sitaxentan—Vomiting—Vinorelbine—ovarian cancer	0.000288	0.000448	CcSEcCtD
Sitaxentan—Dysuria—Epirubicin—ovarian cancer	0.000286	0.000445	CcSEcCtD
Sitaxentan—Rash—Vinorelbine—ovarian cancer	0.000286	0.000444	CcSEcCtD
Sitaxentan—Dermatitis—Vinorelbine—ovarian cancer	0.000285	0.000444	CcSEcCtD
Sitaxentan—Hypotension—Paclitaxel—ovarian cancer	0.000285	0.000443	CcSEcCtD
Sitaxentan—Headache—Vinorelbine—ovarian cancer	0.000284	0.000441	CcSEcCtD
Sitaxentan—Asthma—Doxorubicin—ovarian cancer	0.000283	0.000441	CcSEcCtD
Sitaxentan—Leukopenia—Docetaxel—ovarian cancer	0.000283	0.00044	CcSEcCtD
Sitaxentan—Pollakiuria—Epirubicin—ovarian cancer	0.000283	0.00044	CcSEcCtD
Sitaxentan—EDNRA—Endothelins—AKT1—ovarian cancer	0.000282	0.00438	CbGpPWpGaD
Sitaxentan—Eosinophilia—Doxorubicin—ovarian cancer	0.000281	0.000436	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000279	0.000435	CcSEcCtD
Sitaxentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000279	0.00432	CbGpPWpGaD
Sitaxentan—Weight decreased—Epirubicin—ovarian cancer	0.000277	0.000431	CcSEcCtD
Sitaxentan—Hyperglycaemia—Epirubicin—ovarian cancer	0.000276	0.00043	CcSEcCtD
Sitaxentan—Angina pectoris—Doxorubicin—ovarian cancer	0.000276	0.000429	CcSEcCtD
Sitaxentan—Insomnia—Paclitaxel—ovarian cancer	0.000275	0.000428	CcSEcCtD
Sitaxentan—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000275	0.00427	CbGpPWpGaD
Sitaxentan—Infestation NOS—Epirubicin—ovarian cancer	0.000273	0.000425	CcSEcCtD
Sitaxentan—Infestation—Epirubicin—ovarian cancer	0.000273	0.000425	CcSEcCtD
Sitaxentan—Bronchitis—Doxorubicin—ovarian cancer	0.000272	0.000424	CcSEcCtD
Sitaxentan—Somnolence—Paclitaxel—ovarian cancer	0.000271	0.000421	CcSEcCtD
Sitaxentan—Chest pain—Docetaxel—ovarian cancer	0.000269	0.000419	CcSEcCtD
Sitaxentan—Pancytopenia—Doxorubicin—ovarian cancer	0.000269	0.000418	CcSEcCtD
Sitaxentan—Nausea—Vinorelbine—ovarian cancer	0.000269	0.000418	CcSEcCtD
Sitaxentan—Renal failure—Epirubicin—ovarian cancer	0.000268	0.000417	CcSEcCtD
Sitaxentan—Dyspepsia—Paclitaxel—ovarian cancer	0.000268	0.000417	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000267	0.000416	CcSEcCtD
Sitaxentan—Stomatitis—Epirubicin—ovarian cancer	0.000266	0.000414	CcSEcCtD
Sitaxentan—Jaundice—Epirubicin—ovarian cancer	0.000266	0.000414	CcSEcCtD
Sitaxentan—Conjunctivitis—Epirubicin—ovarian cancer	0.000265	0.000413	CcSEcCtD
Sitaxentan—Dysuria—Doxorubicin—ovarian cancer	0.000265	0.000412	CcSEcCtD
Sitaxentan—Decreased appetite—Paclitaxel—ovarian cancer	0.000265	0.000412	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—DLC1—ovarian cancer	0.000264	0.0041	CbGpPWpGaD
Sitaxentan—Dry mouth—Docetaxel—ovarian cancer	0.000263	0.00041	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000263	0.000409	CcSEcCtD
Sitaxentan—Fatigue—Paclitaxel—ovarian cancer	0.000263	0.000408	CcSEcCtD
Sitaxentan—Pollakiuria—Doxorubicin—ovarian cancer	0.000262	0.000407	CcSEcCtD
Sitaxentan—Constipation—Paclitaxel—ovarian cancer	0.00026	0.000405	CcSEcCtD
Sitaxentan—Pain—Paclitaxel—ovarian cancer	0.00026	0.000405	CcSEcCtD
Sitaxentan—Haematuria—Epirubicin—ovarian cancer	0.00026	0.000405	CcSEcCtD
Sitaxentan—Confusional state—Docetaxel—ovarian cancer	0.00026	0.000405	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000259	0.000402	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000258	0.000402	CcSEcCtD
Sitaxentan—Oedema—Docetaxel—ovarian cancer	0.000258	0.000402	CcSEcCtD
Sitaxentan—Epistaxis—Epirubicin—ovarian cancer	0.000258	0.000401	CcSEcCtD
Sitaxentan—Infection—Docetaxel—ovarian cancer	0.000256	0.000399	CcSEcCtD
Sitaxentan—Weight decreased—Doxorubicin—ovarian cancer	0.000256	0.000399	CcSEcCtD
Sitaxentan—Sinusitis—Epirubicin—ovarian cancer	0.000256	0.000398	CcSEcCtD
Sitaxentan—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000256	0.000397	CcSEcCtD
Sitaxentan—Nervous system disorder—Docetaxel—ovarian cancer	0.000253	0.000394	CcSEcCtD
Sitaxentan—Thrombocytopenia—Docetaxel—ovarian cancer	0.000253	0.000393	CcSEcCtD
Sitaxentan—Infestation—Doxorubicin—ovarian cancer	0.000253	0.000393	CcSEcCtD
Sitaxentan—Infestation NOS—Doxorubicin—ovarian cancer	0.000253	0.000393	CcSEcCtD
Sitaxentan—Tachycardia—Docetaxel—ovarian cancer	0.000252	0.000392	CcSEcCtD
Sitaxentan—Feeling abnormal—Paclitaxel—ovarian cancer	0.000251	0.00039	CcSEcCtD
Sitaxentan—Skin disorder—Docetaxel—ovarian cancer	0.000251	0.00039	CcSEcCtD
Sitaxentan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.00025	0.00388	CbGpPWpGaD
Sitaxentan—Bradycardia—Epirubicin—ovarian cancer	0.00025	0.000388	CcSEcCtD
Sitaxentan—Renal failure—Doxorubicin—ovarian cancer	0.000248	0.000386	CcSEcCtD
Sitaxentan—CYP2C19—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000248	0.00384	CbGpPWpGaD
Sitaxentan—Haemoglobin—Epirubicin—ovarian cancer	0.000246	0.000383	CcSEcCtD
Sitaxentan—Jaundice—Doxorubicin—ovarian cancer	0.000246	0.000383	CcSEcCtD
Sitaxentan—Stomatitis—Doxorubicin—ovarian cancer	0.000246	0.000383	CcSEcCtD
Sitaxentan—Anorexia—Docetaxel—ovarian cancer	0.000246	0.000383	CcSEcCtD
Sitaxentan—Rhinitis—Epirubicin—ovarian cancer	0.000246	0.000382	CcSEcCtD
Sitaxentan—Conjunctivitis—Doxorubicin—ovarian cancer	0.000246	0.000382	CcSEcCtD
Sitaxentan—Haemorrhage—Epirubicin—ovarian cancer	0.000245	0.000381	CcSEcCtD
Sitaxentan—Hepatitis—Epirubicin—ovarian cancer	0.000245	0.000381	CcSEcCtD
Sitaxentan—Urinary tract disorder—Epirubicin—ovarian cancer	0.000242	0.000376	CcSEcCtD
Sitaxentan—Urticaria—Paclitaxel—ovarian cancer	0.000242	0.000376	CcSEcCtD
Sitaxentan—Oedema peripheral—Epirubicin—ovarian cancer	0.000241	0.000376	CcSEcCtD
Sitaxentan—Hypotension—Docetaxel—ovarian cancer	0.000241	0.000375	CcSEcCtD
Sitaxentan—Haematuria—Doxorubicin—ovarian cancer	0.000241	0.000375	CcSEcCtD
Sitaxentan—Body temperature increased—Paclitaxel—ovarian cancer	0.000241	0.000374	CcSEcCtD
Sitaxentan—Urethral disorder—Epirubicin—ovarian cancer	0.00024	0.000374	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000239	0.000372	CcSEcCtD
Sitaxentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000239	0.0037	CbGpPWpGaD
Sitaxentan—Epistaxis—Doxorubicin—ovarian cancer	0.000238	0.000371	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—DOK1—ovarian cancer	0.000238	0.00369	CbGpPWpGaD
Sitaxentan—Sinusitis—Doxorubicin—ovarian cancer	0.000237	0.000369	CcSEcCtD
Sitaxentan—Visual impairment—Epirubicin—ovarian cancer	0.000236	0.000367	CcSEcCtD
Sitaxentan—Insomnia—Docetaxel—ovarian cancer	0.000233	0.000363	CcSEcCtD
Sitaxentan—Bradycardia—Doxorubicin—ovarian cancer	0.000231	0.000359	CcSEcCtD
Sitaxentan—Somnolence—Docetaxel—ovarian cancer	0.00023	0.000357	CcSEcCtD
Sitaxentan—Eye disorder—Epirubicin—ovarian cancer	0.000229	0.000356	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—ovarian cancer	0.000229	0.00355	CbGpPWpGaD
Sitaxentan—Tinnitus—Epirubicin—ovarian cancer	0.000229	0.000355	CcSEcCtD
Sitaxentan—Haemoglobin—Doxorubicin—ovarian cancer	0.000228	0.000354	CcSEcCtD
Sitaxentan—Cardiac disorder—Epirubicin—ovarian cancer	0.000227	0.000354	CcSEcCtD
Sitaxentan—Flushing—Epirubicin—ovarian cancer	0.000227	0.000354	CcSEcCtD
Sitaxentan—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000227	0.00353	CbGpPWpGaD
Sitaxentan—Rhinitis—Doxorubicin—ovarian cancer	0.000227	0.000354	CcSEcCtD
Sitaxentan—Dyspepsia—Docetaxel—ovarian cancer	0.000227	0.000353	CcSEcCtD
Sitaxentan—Haemorrhage—Doxorubicin—ovarian cancer	0.000227	0.000353	CcSEcCtD
Sitaxentan—Hepatitis—Doxorubicin—ovarian cancer	0.000227	0.000353	CcSEcCtD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000226	0.0035	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CXCL8—ovarian cancer	0.000225	0.00349	CbGpPWpGaD
Sitaxentan—Decreased appetite—Docetaxel—ovarian cancer	0.000224	0.000349	CcSEcCtD
Sitaxentan—Hypersensitivity—Paclitaxel—ovarian cancer	0.000224	0.000349	CcSEcCtD
Sitaxentan—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000224	0.000348	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—PPP1CC—ovarian cancer	0.000224	0.00347	CbGpPWpGaD
Sitaxentan—Oedema peripheral—Doxorubicin—ovarian cancer	0.000223	0.000347	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000223	0.000347	CcSEcCtD
Sitaxentan—Fatigue—Docetaxel—ovarian cancer	0.000223	0.000346	CcSEcCtD
Sitaxentan—Angiopathy—Epirubicin—ovarian cancer	0.000222	0.000346	CcSEcCtD
Sitaxentan—Urethral disorder—Doxorubicin—ovarian cancer	0.000222	0.000346	CcSEcCtD
Sitaxentan—Immune system disorder—Epirubicin—ovarian cancer	0.000221	0.000344	CcSEcCtD
Sitaxentan—Mediastinal disorder—Epirubicin—ovarian cancer	0.000221	0.000344	CcSEcCtD
Sitaxentan—Pain—Docetaxel—ovarian cancer	0.000221	0.000343	CcSEcCtD
Sitaxentan—Constipation—Docetaxel—ovarian cancer	0.000221	0.000343	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—ovarian cancer	0.000219	0.0034	CbGpPWpGaD
Sitaxentan—Visual impairment—Doxorubicin—ovarian cancer	0.000219	0.00034	CcSEcCtD
Sitaxentan—Asthenia—Paclitaxel—ovarian cancer	0.000219	0.00034	CcSEcCtD
Sitaxentan—Alopecia—Epirubicin—ovarian cancer	0.000217	0.000337	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—BCL9—ovarian cancer	0.000216	0.00334	CbGpPWpGaD
Sitaxentan—Mental disorder—Epirubicin—ovarian cancer	0.000215	0.000334	CcSEcCtD
Sitaxentan—Malnutrition—Epirubicin—ovarian cancer	0.000213	0.000332	CcSEcCtD
Sitaxentan—Feeling abnormal—Docetaxel—ovarian cancer	0.000213	0.000331	CcSEcCtD
Sitaxentan—Eye disorder—Doxorubicin—ovarian cancer	0.000212	0.00033	CcSEcCtD
Sitaxentan—Tinnitus—Doxorubicin—ovarian cancer	0.000211	0.000329	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	0.000211	0.00327	CbGpPWpGaD
Sitaxentan—Flushing—Doxorubicin—ovarian cancer	0.00021	0.000327	CcSEcCtD
Sitaxentan—Cardiac disorder—Doxorubicin—ovarian cancer	0.00021	0.000327	CcSEcCtD
Sitaxentan—Tension—Epirubicin—ovarian cancer	0.000209	0.000326	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—ovarian cancer	0.000208	0.00323	CbGpPWpGaD
Sitaxentan—Diarrhoea—Paclitaxel—ovarian cancer	0.000208	0.000324	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—ovarian cancer	0.000208	0.00323	CbGpPWpGaD
Sitaxentan—Nervousness—Epirubicin—ovarian cancer	0.000207	0.000322	CcSEcCtD
Sitaxentan—Angiopathy—Doxorubicin—ovarian cancer	0.000206	0.00032	CcSEcCtD
Sitaxentan—Muscle spasms—Epirubicin—ovarian cancer	0.000205	0.000319	CcSEcCtD
Sitaxentan—Immune system disorder—Doxorubicin—ovarian cancer	0.000205	0.000319	CcSEcCtD
Sitaxentan—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000204	0.000318	CcSEcCtD
Sitaxentan—Body temperature increased—Docetaxel—ovarian cancer	0.000204	0.000317	CcSEcCtD
Sitaxentan—EDNRB—G alpha (q) signalling events—PIK3CA—ovarian cancer	0.000202	0.00314	CbGpPWpGaD
Sitaxentan—Dizziness—Paclitaxel—ovarian cancer	0.000201	0.000313	CcSEcCtD
Sitaxentan—Alopecia—Doxorubicin—ovarian cancer	0.0002	0.000312	CcSEcCtD
Sitaxentan—Mental disorder—Doxorubicin—ovarian cancer	0.000199	0.000309	CcSEcCtD
Sitaxentan—Ill-defined disorder—Epirubicin—ovarian cancer	0.000198	0.000308	CcSEcCtD
Sitaxentan—Malnutrition—Doxorubicin—ovarian cancer	0.000197	0.000307	CcSEcCtD
Sitaxentan—Anaemia—Epirubicin—ovarian cancer	0.000197	0.000307	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—ovarian cancer	0.000197	0.00305	CbGpPWpGaD
Sitaxentan—Agitation—Epirubicin—ovarian cancer	0.000196	0.000305	CcSEcCtD
Sitaxentan—Tension—Doxorubicin—ovarian cancer	0.000194	0.000301	CcSEcCtD
Sitaxentan—Vomiting—Paclitaxel—ovarian cancer	0.000194	0.000301	CcSEcCtD
Sitaxentan—Malaise—Epirubicin—ovarian cancer	0.000192	0.000299	CcSEcCtD
Sitaxentan—Rash—Paclitaxel—ovarian cancer	0.000192	0.000299	CcSEcCtD
Sitaxentan—Dermatitis—Paclitaxel—ovarian cancer	0.000192	0.000298	CcSEcCtD
Sitaxentan—Nervousness—Doxorubicin—ovarian cancer	0.000192	0.000298	CcSEcCtD
Sitaxentan—Vertigo—Epirubicin—ovarian cancer	0.000192	0.000298	CcSEcCtD
Sitaxentan—Leukopenia—Epirubicin—ovarian cancer	0.000191	0.000297	CcSEcCtD
Sitaxentan—Headache—Paclitaxel—ovarian cancer	0.000191	0.000297	CcSEcCtD
Sitaxentan—Hypersensitivity—Docetaxel—ovarian cancer	0.00019	0.000296	CcSEcCtD
Sitaxentan—Muscle spasms—Doxorubicin—ovarian cancer	0.00019	0.000295	CcSEcCtD
Sitaxentan—Asthenia—Docetaxel—ovarian cancer	0.000185	0.000288	CcSEcCtD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000184	0.00285	CbGpPWpGaD
Sitaxentan—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000183	0.000285	CcSEcCtD
Sitaxentan—Anaemia—Doxorubicin—ovarian cancer	0.000182	0.000284	CcSEcCtD
Sitaxentan—Chest pain—Epirubicin—ovarian cancer	0.000182	0.000283	CcSEcCtD
Sitaxentan—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000181	0.00281	CbGpPWpGaD
Sitaxentan—Agitation—Doxorubicin—ovarian cancer	0.000181	0.000282	CcSEcCtD
Sitaxentan—Nausea—Paclitaxel—ovarian cancer	0.000181	0.000281	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—ovarian cancer	0.000181	0.0028	CbGpPWpGaD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.00018	0.000281	CcSEcCtD
Sitaxentan—Discomfort—Epirubicin—ovarian cancer	0.000179	0.000279	CcSEcCtD
Sitaxentan—Malaise—Doxorubicin—ovarian cancer	0.000178	0.000277	CcSEcCtD
Sitaxentan—Dry mouth—Epirubicin—ovarian cancer	0.000178	0.000276	CcSEcCtD
Sitaxentan—Vertigo—Doxorubicin—ovarian cancer	0.000177	0.000276	CcSEcCtD
Sitaxentan—Leukopenia—Doxorubicin—ovarian cancer	0.000177	0.000275	CcSEcCtD
Sitaxentan—Diarrhoea—Docetaxel—ovarian cancer	0.000177	0.000275	CcSEcCtD
Sitaxentan—Confusional state—Epirubicin—ovarian cancer	0.000176	0.000273	CcSEcCtD
Sitaxentan—Oedema—Epirubicin—ovarian cancer	0.000174	0.000271	CcSEcCtD
Sitaxentan—Infection—Epirubicin—ovarian cancer	0.000173	0.000269	CcSEcCtD
Sitaxentan—Nervous system disorder—Epirubicin—ovarian cancer	0.000171	0.000266	CcSEcCtD
Sitaxentan—Dizziness—Docetaxel—ovarian cancer	0.000171	0.000266	CcSEcCtD
Sitaxentan—Thrombocytopenia—Epirubicin—ovarian cancer	0.00017	0.000265	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—DOK1—ovarian cancer	0.00017	0.00264	CbGpPWpGaD
Sitaxentan—Tachycardia—Epirubicin—ovarian cancer	0.00017	0.000264	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—HDAC6—ovarian cancer	0.00017	0.00263	CbGpPWpGaD
Sitaxentan—Skin disorder—Epirubicin—ovarian cancer	0.000169	0.000263	CcSEcCtD
Sitaxentan—Chest pain—Doxorubicin—ovarian cancer	0.000168	0.000261	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—PPP2R1A—ovarian cancer	0.000167	0.0026	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	0.000167	0.00259	CbGpPWpGaD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000167	0.00026	CcSEcCtD
Sitaxentan—Discomfort—Doxorubicin—ovarian cancer	0.000166	0.000258	CcSEcCtD
Sitaxentan—Anorexia—Epirubicin—ovarian cancer	0.000166	0.000258	CcSEcCtD
Sitaxentan—Dry mouth—Doxorubicin—ovarian cancer	0.000164	0.000256	CcSEcCtD
Sitaxentan—Vomiting—Docetaxel—ovarian cancer	0.000164	0.000255	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—ovarian cancer	0.000164	0.00254	CbGpPWpGaD
Sitaxentan—Rash—Docetaxel—ovarian cancer	0.000163	0.000253	CcSEcCtD
Sitaxentan—Hypotension—Epirubicin—ovarian cancer	0.000163	0.000253	CcSEcCtD
Sitaxentan—Dermatitis—Docetaxel—ovarian cancer	0.000163	0.000253	CcSEcCtD
Sitaxentan—Confusional state—Doxorubicin—ovarian cancer	0.000162	0.000253	CcSEcCtD
Sitaxentan—Headache—Docetaxel—ovarian cancer	0.000162	0.000252	CcSEcCtD
Sitaxentan—Oedema—Doxorubicin—ovarian cancer	0.000161	0.000251	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—CXCL8—ovarian cancer	0.000161	0.00249	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PPP1CC—ovarian cancer	0.00016	0.00248	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	0.00016	0.00248	CbGpPWpGaD
Sitaxentan—Infection—Doxorubicin—ovarian cancer	0.00016	0.000249	CcSEcCtD
Sitaxentan—Nervous system disorder—Doxorubicin—ovarian cancer	0.000158	0.000246	CcSEcCtD
Sitaxentan—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000158	0.000245	CcSEcCtD
Sitaxentan—Insomnia—Epirubicin—ovarian cancer	0.000157	0.000245	CcSEcCtD
Sitaxentan—Tachycardia—Doxorubicin—ovarian cancer	0.000157	0.000245	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—ovarian cancer	0.000157	0.00243	CbGpPWpGaD
Sitaxentan—Skin disorder—Doxorubicin—ovarian cancer	0.000156	0.000243	CcSEcCtD
Sitaxentan—Somnolence—Epirubicin—ovarian cancer	0.000155	0.000241	CcSEcCtD
Sitaxentan—Anorexia—Doxorubicin—ovarian cancer	0.000154	0.000239	CcSEcCtD
Sitaxentan—Nausea—Docetaxel—ovarian cancer	0.000153	0.000238	CcSEcCtD
Sitaxentan—Dyspepsia—Epirubicin—ovarian cancer	0.000153	0.000238	CcSEcCtD
Sitaxentan—Decreased appetite—Epirubicin—ovarian cancer	0.000151	0.000235	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	0.000151	0.00234	CbGpPWpGaD
Sitaxentan—Hypotension—Doxorubicin—ovarian cancer	0.000151	0.000234	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.00015	0.000234	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—YAP1—ovarian cancer	0.00015	0.00233	CbGpPWpGaD
Sitaxentan—Fatigue—Epirubicin—ovarian cancer	0.00015	0.000233	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—ovarian cancer	0.000149	0.00231	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—ovarian cancer	0.000149	0.00231	CbGpPWpGaD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000149	0.00231	CbGpPWpGaD
Sitaxentan—Constipation—Epirubicin—ovarian cancer	0.000149	0.000232	CcSEcCtD
Sitaxentan—Pain—Epirubicin—ovarian cancer	0.000149	0.000232	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—XIAP—ovarian cancer	0.000147	0.00228	CbGpPWpGaD
Sitaxentan—Insomnia—Doxorubicin—ovarian cancer	0.000146	0.000227	CcSEcCtD
Sitaxentan—EDNRA—G alpha (q) signalling events—PIK3CA—ovarian cancer	0.000145	0.00224	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Epirubicin—ovarian cancer	0.000143	0.000223	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—SMARCA4—ovarian cancer	0.000143	0.00222	CbGpPWpGaD
Sitaxentan—Somnolence—Doxorubicin—ovarian cancer	0.000143	0.000223	CcSEcCtD
Sitaxentan—Dyspepsia—Doxorubicin—ovarian cancer	0.000142	0.000221	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—ovarian cancer	0.000141	0.00218	CbGpPWpGaD
Sitaxentan—Decreased appetite—Doxorubicin—ovarian cancer	0.00014	0.000218	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—EREG—ovarian cancer	0.00014	0.00217	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000139	0.000216	CcSEcCtD
Sitaxentan—Fatigue—Doxorubicin—ovarian cancer	0.000139	0.000216	CcSEcCtD
Sitaxentan—Urticaria—Epirubicin—ovarian cancer	0.000138	0.000215	CcSEcCtD
Sitaxentan—Pain—Doxorubicin—ovarian cancer	0.000138	0.000214	CcSEcCtD
Sitaxentan—Constipation—Doxorubicin—ovarian cancer	0.000138	0.000214	CcSEcCtD
Sitaxentan—Body temperature increased—Epirubicin—ovarian cancer	0.000138	0.000214	CcSEcCtD
Sitaxentan—Feeling abnormal—Doxorubicin—ovarian cancer	0.000133	0.000206	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—CYP1B1—ovarian cancer	0.000132	0.00204	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PGR—ovarian cancer	0.000131	0.00203	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP1B1—ovarian cancer	0.00013	0.00201	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—ovarian cancer	0.000129	0.00201	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Epirubicin—ovarian cancer	0.000128	0.0002	CcSEcCtD
Sitaxentan—Urticaria—Doxorubicin—ovarian cancer	0.000128	0.000199	CcSEcCtD
Sitaxentan—Body temperature increased—Doxorubicin—ovarian cancer	0.000127	0.000198	CcSEcCtD
Sitaxentan—Asthenia—Epirubicin—ovarian cancer	0.000125	0.000194	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—PIK3CG—ovarian cancer	0.000123	0.00191	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PARP1—ovarian cancer	0.000122	0.00189	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HDAC6—ovarian cancer	0.000121	0.00188	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—CYP1B1—ovarian cancer	0.00012	0.00186	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PPP2R1A—ovarian cancer	0.00012	0.00186	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	0.00012	0.00186	CbGpPWpGaD
Sitaxentan—Diarrhoea—Epirubicin—ovarian cancer	0.000119	0.000185	CcSEcCtD
Sitaxentan—Hypersensitivity—Doxorubicin—ovarian cancer	0.000119	0.000185	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000118	0.00184	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL6ST—ovarian cancer	0.000117	0.00181	CbGpPWpGaD
Sitaxentan—Asthenia—Doxorubicin—ovarian cancer	0.000116	0.00018	CcSEcCtD
Sitaxentan—Dizziness—Epirubicin—ovarian cancer	0.000115	0.000179	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—CXCL8—ovarian cancer	0.000115	0.00178	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	0.000115	0.00178	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PIK3CG—ovarian cancer	0.000112	0.00174	CbGpPWpGaD
Sitaxentan—Vomiting—Epirubicin—ovarian cancer	0.000111	0.000172	CcSEcCtD
Sitaxentan—Diarrhoea—Doxorubicin—ovarian cancer	0.00011	0.000171	CcSEcCtD
Sitaxentan—Rash—Epirubicin—ovarian cancer	0.00011	0.000171	CcSEcCtD
Sitaxentan—Dermatitis—Epirubicin—ovarian cancer	0.00011	0.000171	CcSEcCtD
Sitaxentan—Headache—Epirubicin—ovarian cancer	0.000109	0.00017	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—PIK3CD—ovarian cancer	0.000108	0.00168	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—YAP1—ovarian cancer	0.000107	0.00167	CbGpPWpGaD
Sitaxentan—Dizziness—Doxorubicin—ovarian cancer	0.000107	0.000166	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—XIAP—ovarian cancer	0.000105	0.00163	CbGpPWpGaD
Sitaxentan—Nausea—Epirubicin—ovarian cancer	0.000103	0.000161	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—SMARCA4—ovarian cancer	0.000103	0.00159	CbGpPWpGaD
Sitaxentan—Vomiting—Doxorubicin—ovarian cancer	0.000102	0.000159	CcSEcCtD
Sitaxentan—Rash—Doxorubicin—ovarian cancer	0.000102	0.000158	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000102	0.00157	CbGpPWpGaD
Sitaxentan—Dermatitis—Doxorubicin—ovarian cancer	0.000101	0.000158	CcSEcCtD
Sitaxentan—Headache—Doxorubicin—ovarian cancer	0.000101	0.000157	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—EREG—ovarian cancer	0.0001	0.00155	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PPP2R1A—ovarian cancer	9.89e-05	0.00153	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PIK3CD—ovarian cancer	9.85e-05	0.00153	CbGpPWpGaD
Sitaxentan—Nausea—Doxorubicin—ovarian cancer	9.57e-05	0.000149	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—PIK3CB—ovarian cancer	9.45e-05	0.00147	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PGR—ovarian cancer	9.38e-05	0.00146	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	9.26e-05	0.00144	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCL8—ovarian cancer	9.08e-05	0.00141	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CG—ovarian cancer	8.83e-05	0.00137	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PARP1—ovarian cancer	8.72e-05	0.00135	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—IL2—ovarian cancer	8.68e-05	0.00135	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PIK3CB—ovarian cancer	8.58e-05	0.00133	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL6ST—ovarian cancer	8.35e-05	0.00129	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CXCL8—ovarian cancer	8.25e-05	0.00128	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NME2—ovarian cancer	8.03e-05	0.00124	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CG—ovarian cancer	8.02e-05	0.00124	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	7.92e-05	0.00123	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL2—ovarian cancer	7.88e-05	0.00122	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TERT—ovarian cancer	7.86e-05	0.00122	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	7.81e-05	0.00121	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CD—ovarian cancer	7.76e-05	0.0012	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NME2—ovarian cancer	7.32e-05	0.00114	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CAV1—ovarian cancer	7.27e-05	0.00113	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PPP2R1A—ovarian cancer	7.08e-05	0.0011	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CD—ovarian cancer	7.05e-05	0.00109	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ESR1—ovarian cancer	7e-05	0.00109	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL6ST—ovarian cancer	6.89e-05	0.00107	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	6.81e-05	0.00106	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CB—ovarian cancer	6.77e-05	0.00105	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—APC—ovarian cancer	6.62e-05	0.00103	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CG—ovarian cancer	6.62e-05	0.00103	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—NRAS—ovarian cancer	6.62e-05	0.00103	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCL8—ovarian cancer	6.5e-05	0.00101	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—MAPK3—ovarian cancer	6.34e-05	0.000983	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—IL2—ovarian cancer	6.21e-05	0.000964	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	6.21e-05	0.000963	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CB—ovarian cancer	6.14e-05	0.000953	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—MAPK1—ovarian cancer	6.03e-05	0.000935	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—EGFR—ovarian cancer	6.03e-05	0.000935	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CXCL8—ovarian cancer	5.9e-05	0.000916	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CD—ovarian cancer	5.82e-05	0.000902	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—PIK3CA—ovarian cancer	5.76e-05	0.000894	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—KRAS—ovarian cancer	5.7e-05	0.000883	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL2—ovarian cancer	5.64e-05	0.000875	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TERT—ovarian cancer	5.62e-05	0.000872	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	5.55e-05	0.000861	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PIK3CA—ovarian cancer	5.23e-05	0.000812	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CAV1—ovarian cancer	5.2e-05	0.000806	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYTB—ovarian cancer	5.17e-05	0.000802	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ERBB2—ovarian cancer	5.14e-05	0.000797	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MTOR—ovarian cancer	5.07e-05	0.000786	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CB—ovarian cancer	5.07e-05	0.000786	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	5.06e-05	0.000785	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	5.06e-05	0.000784	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ESR1—ovarian cancer	5.01e-05	0.000777	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL6ST—ovarian cancer	4.93e-05	0.000764	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CXCL8—ovarian cancer	4.87e-05	0.000756	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—HRAS—ovarian cancer	4.84e-05	0.000751	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NME2—ovarian cancer	4.83e-05	0.000749	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CDKN1B—ovarian cancer	4.76e-05	0.000738	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CG—ovarian cancer	4.74e-05	0.000735	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—APC—ovarian cancer	4.74e-05	0.000735	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—NRAS—ovarian cancer	4.74e-05	0.000735	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYTB—ovarian cancer	4.72e-05	0.000731	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—AKT1—ovarian cancer	4.71e-05	0.00073	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CASP3—ovarian cancer	4.66e-05	0.000723	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL2—ovarian cancer	4.66e-05	0.000722	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL6—ovarian cancer	4.63e-05	0.000719	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.61e-05	0.000715	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCND1—ovarian cancer	4.54e-05	0.000704	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—MAPK3—ovarian cancer	4.54e-05	0.000703	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—BRIP1—ovarian cancer	4.52e-05	0.000701	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PPP1CC—ovarian cancer	4.52e-05	0.000701	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CTNNB1—ovarian cancer	4.5e-05	0.000697	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MMP9—ovarian cancer	4.41e-05	0.000684	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PTEN—ovarian cancer	4.38e-05	0.00068	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—MAPK1—ovarian cancer	4.32e-05	0.000669	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—EGFR—ovarian cancer	4.32e-05	0.000669	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—AKT1—ovarian cancer	4.28e-05	0.000663	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CD—ovarian cancer	4.16e-05	0.000646	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CA—ovarian cancer	4.12e-05	0.00064	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PPP1CC—ovarian cancer	4.12e-05	0.000639	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—BRIP1—ovarian cancer	4.12e-05	0.000639	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—KRAS—ovarian cancer	4.08e-05	0.000632	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—VEGFA—ovarian cancer	3.96e-05	0.000614	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—STAT3—ovarian cancer	3.92e-05	0.000608	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NRAS—ovarian cancer	3.91e-05	0.000606	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CA—ovarian cancer	3.75e-05	0.000581	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MAPK3—ovarian cancer	3.74e-05	0.000581	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ERBB2—ovarian cancer	3.68e-05	0.00057	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MYC—ovarian cancer	3.64e-05	0.000565	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MTOR—ovarian cancer	3.63e-05	0.000563	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CB—ovarian cancer	3.63e-05	0.000563	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MAPK1—ovarian cancer	3.56e-05	0.000552	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EGFR—ovarian cancer	3.56e-05	0.000552	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CXCL8—ovarian cancer	3.49e-05	0.000541	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—HRAS—ovarian cancer	3.47e-05	0.000537	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CDKN1B—ovarian cancer	3.41e-05	0.000528	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—AKT1—ovarian cancer	3.37e-05	0.000523	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KRAS—ovarian cancer	3.37e-05	0.000522	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CASP3—ovarian cancer	3.34e-05	0.000518	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL2—ovarian cancer	3.33e-05	0.000517	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL6—ovarian cancer	3.32e-05	0.000514	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.3e-05	0.000511	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCND1—ovarian cancer	3.25e-05	0.000504	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CTNNB1—ovarian cancer	3.22e-05	0.000499	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MMP9—ovarian cancer	3.15e-05	0.000489	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTEN—ovarian cancer	3.14e-05	0.000486	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYTB—ovarian cancer	3.11e-05	0.000482	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CA—ovarian cancer	3.09e-05	0.000479	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—AKT1—ovarian cancer	3.06e-05	0.000474	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—YAP1—ovarian cancer	3.03e-05	0.00047	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3e-05	0.000466	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3e-05	0.000465	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—ovarian cancer	2.99e-05	0.000464	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HRAS—ovarian cancer	2.86e-05	0.000444	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—VEGFA—ovarian cancer	2.83e-05	0.000439	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—STAT3—ovarian cancer	2.81e-05	0.000435	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NRAS—ovarian cancer	2.8e-05	0.000434	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—YAP1—ovarian cancer	2.77e-05	0.000429	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL6—ovarian cancer	2.74e-05	0.000425	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.74e-05	0.000424	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PPP1CC—ovarian cancer	2.72e-05	0.000422	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—BRIP1—ovarian cancer	2.72e-05	0.000422	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MAPK3—ovarian cancer	2.68e-05	0.000416	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.64e-05	0.000409	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MYC—ovarian cancer	2.61e-05	0.000404	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MAPK1—ovarian cancer	2.55e-05	0.000395	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EGFR—ovarian cancer	2.55e-05	0.000395	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AKT1—ovarian cancer	2.53e-05	0.000392	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—FASN—ovarian cancer	2.47e-05	0.000383	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC5A5—ovarian cancer	2.43e-05	0.000377	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KRAS—ovarian cancer	2.41e-05	0.000373	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.41e-05	0.000373	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC2A1—ovarian cancer	2.35e-05	0.000364	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.3e-05	0.000357	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—FASN—ovarian cancer	2.25e-05	0.00035	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP1B1—ovarian cancer	2.25e-05	0.000349	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC5A5—ovarian cancer	2.22e-05	0.000344	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CA—ovarian cancer	2.21e-05	0.000343	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC2A1—ovarian cancer	2.14e-05	0.000332	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—ovarian cancer	2.14e-05	0.000332	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.1e-05	0.000325	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP1B1—ovarian cancer	2.05e-05	0.000318	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HRAS—ovarian cancer	2.05e-05	0.000317	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	2e-05	0.00031	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.99e-05	0.000308	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL6—ovarian cancer	1.96e-05	0.000304	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ABCB1—ovarian cancer	1.85e-05	0.000288	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—YAP1—ovarian cancer	1.82e-05	0.000283	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TYMS—ovarian cancer	1.82e-05	0.000282	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	1.82e-05	0.000282	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.81e-05	0.000281	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AKT1—ovarian cancer	1.81e-05	0.00028	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ABCB1—ovarian cancer	1.69e-05	0.000262	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TYMS—ovarian cancer	1.66e-05	0.000257	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—FASN—ovarian cancer	1.49e-05	0.000231	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CAV1—ovarian cancer	1.47e-05	0.000228	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.46e-05	0.000227	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.41e-05	0.000219	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.4e-05	0.000217	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.35e-05	0.00021	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CAV1—ovarian cancer	1.34e-05	0.000207	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CG—ovarian cancer	1.34e-05	0.000207	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.28e-05	0.000198	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.22e-05	0.000189	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.2e-05	0.000186	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CD—ovarian cancer	1.18e-05	0.000182	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.12e-05	0.000173	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TYMS—ovarian cancer	1.1e-05	0.00017	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.07e-05	0.000166	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CB—ovarian cancer	1.02e-05	0.000159	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CB—ovarian cancer	9.34e-06	0.000145	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTEN—ovarian cancer	8.85e-06	0.000137	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CAV1—ovarian cancer	8.82e-06	0.000137	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTEN—ovarian cancer	8.07e-06	0.000125	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CG—ovarian cancer	8.04e-06	0.000125	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CD—ovarian cancer	7.07e-06	0.00011	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CA—ovarian cancer	6.24e-06	9.68e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CB—ovarian cancer	6.16e-06	9.55e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CA—ovarian cancer	5.69e-06	8.83e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTEN—ovarian cancer	5.32e-06	8.25e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—AKT1—ovarian cancer	5.1e-06	7.91e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—AKT1—ovarian cancer	4.65e-06	7.21e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CA—ovarian cancer	3.75e-06	5.82e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—AKT1—ovarian cancer	3.07e-06	4.76e-05	CbGpPWpGaD
